GlassScriptPhysician profile
Adam N Williams
NPI 1265433445
$138,045.28
in general payments reported to CMS, 2019-2025
28 companies · $14K in 2025
The $14K reported for 2025 was more than what 90% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $2,168 · 2021: $15K · 2022: $23K · 2023: $35K · 2024: $35K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $65K · Travel and Lodging: $8,745 · Food and Beverage: $7,984 · Consulting Fee: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $65,262.40 |
| Travel and Lodging | $8,745.20 |
| Food and Beverage | $7,984.22 |
| Consulting Fee | $1,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $56,281.68 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Genzyme Corporation | $37,182.46 | 2021-2025 | |
| Genentech USA, INC. | $34,037.00 | 2019-2025 | Xolair |
| Amgen INC. | $5,708.63 | 2022-2025 | Tezspire |
| Glaxosmithkline, LLC. | $852.33 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $626.39 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $625.36 | 2019-2025 | Dupixent |
| Csl Behring | $551.05 | 2020-2025 | Hizentra, Haegarda, Andembry |
| Blueprint Medicines Corporation | $374.81 | 2022-2024 | Ayvakit |
| Abbvie INC. | $233.35 | 2022-2023 | Rinvoq |
| Optinose US, INC. | $179.65 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $175.00 | 2021 | |
| Lilly USA, LLC | $157.54 | 2024-2025 | Ebglyss, Taltz |
| Ars Pharmaceuticals Operations, INC. | $125.00 | 2025 | Neffy |
| Takeda Pharmaceuticals U.S.A., INC. | $120.38 | 2024-2025 | Eohilia, Cuvitru, Takhzyro |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $110.09 | 2025 | Dupixent |
| Biocryst US Sales Co., LLC | $110.00 | 2021 | |
| Bio Products Laboratory USA, INC. | $89.59 | 2022-2023 | Gammaplex, Coagadex |
| Grifols USA, LLC | $89.40 | 2019-2024 | Xembify |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.99 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $75.00 | 2022 | |
| Octapharma USA, INC. | $70.71 | 2019-2020 | |
| Ionis Pharmaceuticals, INC. | $60.24 | 2025 | Dawnzera |
| Pharming Healthcare, INC. | $49.60 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $39.61 | 2019 | |
| Biocryst Pharmaceuticals, INC. | $21.73 | 2020 | |
| Circassia INC. | $14.69 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.